Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 391

1.

Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription.

Gao R, Chakraborty A, Geater C, Pradhan S, Gordon KL, Snowden J, Yuan S, Dickey AS, Choudhary S, Ashizawa T, Ellerby LM, La Spada AR, Thompson LM, Hazra TK, Sarkar PS.

Elife. 2019 Apr 17;8. pii: e42988. doi: 10.7554/eLife.42988.

2.

Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.

Nonomura C, Otsuka M, Kondou R, Iizuka A, Miyata H, Ashizawa T, Sakura N, Yoshikawa S, Kiyohara Y, Ohshima K, Urakami K, Nagashima T, Ohnami S, Kusuhara M, Mitsuya K, Hayashi N, Nakasu Y, Mochizuki T, Yamaguchi K, Akiyama Y.

Immunol Lett. 2019 Apr;208:52-59. doi: 10.1016/j.imlet.2019.02.004. Epub 2019 Mar 14.

3.

Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor.

Lai RY, Tomishon D, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez CM, Schmahmann JD, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Cerebellum. 2019 Jun;18(3):519-526. doi: 10.1007/s12311-019-01016-6.

PMID:
30830673
4.

99mTc-TRODAT-1 SPECT Showing Dopaminergic Deficiency in a Patient with Spinocerebellar Ataxia Type 10 and Parkinsonism.

Fabiani G, Martins R, Ashizawa T, Germiniani FMB, Teive HAG.

Mov Disord Clin Pract. 2018 Nov 16;6(1):85-87. doi: 10.1002/mdc3.12700. eCollection 2019 Jan. No abstract available.

PMID:
30746424
5.

A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.

Iizuka A, Nonomura C, Ashizawa T, Kondou R, Ohshima K, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, Yamaguchi K, Akiyama Y.

Clin Cancer Res. 2019 May 1;25(9):2925-2934. doi: 10.1158/1078-0432.CCR-17-3123. Epub 2019 Feb 8.

PMID:
30737243
6.

Consensus-based care recommendations for adults with myotonic dystrophy type 1.

Ashizawa T, Gagnon C, Groh WJ, Gutmann L, Johnson NE, Meola G, Moxley R 3rd, Pandya S, Rogers MT, Simpson E, Angeard N, Bassez G, Berggren KN, Bhakta D, Bozzali M, Broderick A, Byrne JLB, Campbell C, Cup E, Day JW, De Mattia E, Duboc D, Duong T, Eichinger K, Ekstrom AB, van Engelen B, Esparis B, Eymard B, Ferschl M, Gadalla SM, Gallais B, Goodglick T, Heatwole C, Hilbert J, Holland V, Kierkegaard M, Koopman WJ, Lane K, Maas D, Mankodi A, Mathews KD, Monckton DG, Moser D, Nazarian S, Nguyen L, Nopoulos P, Petty R, Phetteplace J, Puymirat J, Raman S, Richer L, Roma E, Sampson J, Sansone V, Schoser B, Sterling L, Statland J, Subramony SH, Tian C, Trujillo C, Tomaselli G, Turner C, Venance S, Verma A, White M, Winblad S.

Neurol Clin Pract. 2018 Dec;8(6):507-520. doi: 10.1212/CPJ.0000000000000531. Review.

7.

Polymorphisms in DNA methylation-related genes are linked to the phenotype of Machado-Joseph disease.

Ding D, Wang C, Chen Z, Peng H, Li K, Zhou X, Peng Y, Wang P, Hou X, Li T, Qiu R, Xia K, Sequeiros J, Ashizawa T, Tang B, Jiang H.

Neurobiol Aging. 2019 Mar;75:225.e1-225.e8. doi: 10.1016/j.neurobiolaging.2018.11.002. Epub 2018 Nov 16.

PMID:
30554804
8.

Human iPSC Models to Study Orphan Diseases: Muscular Dystrophies.

Xia G, Terada N, Ashizawa T.

Curr Stem Cell Rep. 2018;4(4):299-309. doi: 10.1007/s40778-018-0145-5. Epub 2018 Oct 4. Review.

9.

Author Correction: Spinocerebellar ataxias: prospects and challenges for therapy development.

Ashizawa T, Öz G, Paulson HL.

Nat Rev Neurol. 2018 Dec;14(12):749. doi: 10.1038/s41582-018-0102-z.

PMID:
30410042
10.

Classification of tumor microenvironment immune types based on immune response-associated gene expression.

Kondou R, Iizuka A, Nonomura C, Miyata H, Ashizawa T, Nagashima T, Ohshima K, Urakami K, Kusuhara M, Yamaguchi K, Akiyama Y.

Int J Oncol. 2019 Jan;54(1):219-228. doi: 10.3892/ijo.2018.4617. Epub 2018 Nov 2.

PMID:
30387832
11.

Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.

Wang Y, Hao L, Wang H, Santostefano K, Thapa A, Cleary J, Li H, Guo X, Terada N, Ashizawa T, Xia G.

Mol Ther. 2018 Nov 7;26(11):2617-2630. doi: 10.1016/j.ymthe.2018.09.003. Epub 2018 Sep 11.

12.

SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F.

Ayhan F, Perez BA, Shorrock HK, Zu T, Banez-Coronel M, Reid T, Furuya H, Clark HB, Troncoso JC, Ross CA, Subramony SH, Ashizawa T, Wang ET, Yachnis AT, Ranum LP.

EMBO J. 2018 Oct 1;37(19). pii: e99023. doi: 10.15252/embj.201899023. Epub 2018 Sep 11.

PMID:
30206144
13.

Spinocerebellar ataxias: prospects and challenges for therapy development.

Ashizawa T, Öz G, Paulson HL.

Nat Rev Neurol. 2018 Oct;14(10):590-605. doi: 10.1038/s41582-018-0051-6. Review. Erratum in: Nat Rev Neurol. 2018 Dec;14(12):749.

14.

Longitudinal analysis of contrast acuity in Friedreich ataxia.

Hamedani AG, Hauser LA, Perlman S, Mathews K, Wilmot GR, Zesiewicz T, Subramony SH, Ashizawa T, Delatycki MB, Brocht A, Lynch DR.

Neurol Genet. 2018 Jul 23;4(4):e250. doi: 10.1212/NXG.0000000000000250. eCollection 2018 Aug.

15.

Intravenously Administered Novel Liposomes, DCL64, Deliver Oligonucleotides to Cerebellar Purkinje Cells.

Ashizawa AT, Holt J, Faust K, Liu W, Tiwari A, Zhang N, Ashizawa T.

Cerebellum. 2019 Feb;18(1):99-108. doi: 10.1007/s12311-018-0961-2.

PMID:
29987489
16.

Olfactory Function in SCA10.

Moscovich M, Munhoz RP, Moro A, Raskin S, McFarland K, Ashizawa T, Teive HAG, Silveira-Moriyama L.

Cerebellum. 2019 Feb;18(1):85-90. doi: 10.1007/s12311-018-0954-1.

PMID:
29922950
17.

Body composition in Spinocerebellar ataxia type 3 and 10 patients: Comparative study with control group.

Leite CMBA, Schieferdecker MEM, Frehner C, Munhoz RP, Ashizawa T, Teive HAG.

Nutr Neurosci. 2018 May 7:1-6. doi: 10.1080/1028415X.2018.1469282. [Epub ahead of print]

PMID:
29734917
18.

Sleep disorders in spinocerebellar ataxia type 10.

London E, Camargo CHF, Zanatta A, Crippa AC, Raskin S, Munhoz RP, Ashizawa T, Teive HAG.

J Sleep Res. 2018 Oct;27(5):e12688. doi: 10.1111/jsr.12688. Epub 2018 Apr 6.

PMID:
29624773
19.

Intron retention induced by microsatellite expansions as a disease biomarker.

Sznajder ŁJ, Thomas JD, Carrell EM, Reid T, McFarland KN, Cleary JD, Oliveira R, Nutter CA, Bhatt K, Sobczak K, Ashizawa T, Thornton CA, Ranum LPW, Swanson MS.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):4234-4239. doi: 10.1073/pnas.1716617115. Epub 2018 Apr 2.

20.

Spinocerebellar ataxias type 3 and 10: Onset and progression of ataxia during pregnancy and puerperium.

Silva GV, Bonilha P, Moro A, Munhoz R, Raskin S, Ashizawa T, Nascimento FA, Teive HAG.

Parkinsonism Relat Disord. 2018 Jul;52:119-120. doi: 10.1016/j.parkreldis.2018.03.025. Epub 2018 Mar 27. No abstract available.

PMID:
29609848
21.

A crystal ball for survival for spinocerebellar ataxias?

Ashizawa T.

Lancet Neurol. 2018 Apr;17(4):292-294. doi: 10.1016/S1474-4422(18)30088-7. Epub 2018 Mar 13. No abstract available.

PMID:
29553373
22.

Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP, Mizusawa H, Schöls L, Shaw JD, Dubinsky RM, Armstrong MJ, Gronseth GS, Sullivan KL.

Neurology. 2018 Mar 6;90(10):464-471. doi: 10.1212/WNL.0000000000005055. Epub 2018 Feb 9.

23.

Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.

Akiyama Y, Kiyohara Y, Yoshikawa S, Otsuka M, Kondou R, Nonomura C, Miyata H, Iizuka A, Ashizawa T, Ohshima K, Urakami K, Nagashima T, Kusuhara M, Sugino T, Yamaguchi K.

Oncol Rep. 2018 Mar;39(3):1125-1131. doi: 10.3892/or.2017.6173. Epub 2017 Dec 21.

PMID:
29286146
24.

C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias.

Figueroa KP, Gan SR, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Pulst SM, Kuo SH.

Mov Disord. 2018 Mar;33(3):497-498. doi: 10.1002/mds.27258. Epub 2017 Nov 29. No abstract available.

25.

Correction to: SPG7 and Impaired Emotional Communication.

Zhang L, McFarland KN, Subramony SH, Heilman KM, Ashizawa T.

Cerebellum. 2017 Dec;16(5-6):991. doi: 10.1007/s12311-017-0901-6.

PMID:
29181771
26.

Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.

Mikami S, Kawasaki M, Ikeda S, Negoro N, Nakamura S, Nomura I, Ashizawa T, Kokubo H, Hoffman ID, Zou H, Oki H, Uchiyama N, Hiura Y, Miyamoto M, Itou Y, Nakashima M, Iwashita H, Taniguchi T.

Chem Pharm Bull (Tokyo). 2017;65(11):1058-1077. doi: 10.1248/cpb.c17-00564.

27.

Dystonia and ataxia progression in spinocerebellar ataxias.

Kuo PH, Gan SR, Wang J, Lo RY, Figueroa KP, Tomishon D, Pulst SM, Perlman S, Wilmot G, Gomez CM, Schmahmann JD, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Parkinsonism Relat Disord. 2017 Dec;45:75-80. doi: 10.1016/j.parkreldis.2017.10.007. Epub 2017 Oct 23.

28.

Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias.

Gan SR, Wang J, Figueroa KP, Pulst SM, Tomishon D, Lee D, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Tremor Other Hyperkinet Mov (N Y). 2017 Oct 9;7:492. doi: 10.7916/D8GM8KRH. eCollection 2017.

29.

RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.

Zu T, Cleary JD, Liu Y, Bañez-Coronel M, Bubenik JL, Ayhan F, Ashizawa T, Xia G, Clark HB, Yachnis AT, Swanson MS, Ranum LPW.

Neuron. 2017 Sep 13;95(6):1292-1305.e5. doi: 10.1016/j.neuron.2017.08.039.

30.

Parkinson's disease associated with pure ATXN10 repeat expansion.

Schüle B, McFarland KN, Lee K, Tsai YC, Nguyen KD, Sun C, Liu M, Byrne C, Gopi R, Huang N, Langston JW, Clark T, Gil FJJ, Ashizawa T.

NPJ Parkinsons Dis. 2017 Sep 5;3:27. doi: 10.1038/s41531-017-0029-x. eCollection 2017.

31.

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.

Mikami S, Nakamura S, Ashizawa T, Nomura I, Kawasaki M, Sasaki S, Oki H, Kokubo H, Hoffman ID, Zou H, Uchiyama N, Nakashima K, Kamiguchi N, Imada H, Suzuki N, Iwashita H, Taniguchi T.

J Med Chem. 2017 Sep 28;60(18):7677-7702. doi: 10.1021/acs.jmedchem.7b00807. Epub 2017 Sep 5.

PMID:
28796496
32.

The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.

Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Asai A, Ito M, Kiyohara Y, Yamaguchi K.

Immunol Lett. 2017 Oct;190:20-25. doi: 10.1016/j.imlet.2017.07.005. Epub 2017 Jul 15.

PMID:
28716484
33.

Spinocerebellar Ataxia Type 1.

Opal P, Ashizawa T.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
1998 Oct 1 [updated 2017 Jun 22].

34.

Nonmotor Symptoms in Patients with Spinocerebellar Ataxia Type 10.

Moro A, Munhoz RP, Moscovich M, Arruda WO, Raskin S, Silveira-Moriyama L, Ashizawa T, Teive HAG.

Cerebellum. 2017 Dec;16(5-6):938-944. doi: 10.1007/s12311-017-0869-2.

35.

Inheritance patterns of ATCCT repeat interruptions in spinocerebellar ataxia type 10 (SCA10) expansions.

Landrian I, McFarland KN, Liu J, Mulligan CJ, Rasmussen A, Ashizawa T.

PLoS One. 2017 Apr 19;12(4):e0175958. doi: 10.1371/journal.pone.0175958. eCollection 2017.

36.

A Comparative Optical Coherence Tomography Study of Spinocerebellar Ataxia Types 3 and 10.

Spina Tensini F, Sato MT, Shiokawa N, Ashizawa T, Teive HAG.

Cerebellum. 2017 Aug;16(4):797-801. doi: 10.1007/s12311-017-0856-7.

PMID:
28401494
37.

Ubiquitin-related network underlain by (CAG)n loci modulate age at onset in Machado-Joseph disease.

Chen Z, Wang C, Zheng C, Long Z, Cao L, Li X, Shang H, Yin X, Zhang B, Liu J, Ding D, Peng Y, Peng H, Ye W, Qiu R, Pan Q, Xia K, Chen S, Sequeiros J, Ashizawa T, Tang B, Jiang H; Chinese Clinical Research Cooperative Group for Spinocerebellar Ataxias (CCRCG-SCA).

Brain. 2017 Apr 1;140(4):e25. doi: 10.1093/brain/awx028. No abstract available.

PMID:
28334945
38.

RNA toxicity and foci formation in microsatellite expansion diseases.

Zhang N, Ashizawa T.

Curr Opin Genet Dev. 2017 Jun;44:17-29. doi: 10.1016/j.gde.2017.01.005. Epub 2017 Feb 14. Review.

39.

Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.

Miyata H, Ashizawa T, Iizuka A, Kondou R, Nonomura C, Sugino T, Urakami K, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K, Akiyama Y.

Cancer Genomics Proteomics. 2017 Jan 2;14(1):83-91.

40.

The Initial Symptom and Motor Progression in Spinocerebellar Ataxias.

Luo L, Wang J, Lo RY, Figueroa KP, Pulst SM, Kuo PH, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Cerebellum. 2017 Jun;16(3):615-622. doi: 10.1007/s12311-016-0836-3.

41.

Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.

Iizuka A, Kondou R, Nonomura C, Ashizawa T, Ohshima K, Kusuhara M, Isaka M, Ohde Y, Yamaguchi K, Akiyama Y.

Oncol Rep. 2016 Nov;36(5):2625-2632. doi: 10.3892/or.2016.5084. Epub 2016 Sep 12.

PMID:
27632942
42.

Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells.

Akiyama Y, Nonomura C, Kondou R, Miyata H, Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K.

Int J Oncol. 2016 Sep;49(3):1099-107. doi: 10.3892/ijo.2016.3586. Epub 2016 Jun 29.

PMID:
27573705
43.

SPG7 and Impaired Emotional Communication.

Zhang L, McFarland KN, Subramony SH, Heilman KM, Ashizawa T.

Cerebellum. 2017 Apr;16(2):595-598. doi: 10.1007/s12311-016-0818-5. Erratum in: Cerebellum. 2017 Nov 27;:.

44.

ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis.

Li PP, Sun X, Xia G, Arbez N, Paul S, Zhu S, Peng HB, Ross CA, Koeppen AH, Margolis RL, Pulst SM, Ashizawa T, Rudnicki DD.

Ann Neurol. 2016 Oct;80(4):600-15. doi: 10.1002/ana.24761.

45.

Ataxia.

Ashizawa T, Xia G.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1208-26. doi: 10.1212/CON.0000000000000362. Review.

46.

Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.

Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, Yamaguchi K, Katano I, Ito M, Akiyama Y.

Clin Cancer Res. 2017 Jan 1;23(1):149-158. doi: 10.1158/1078-0432.CCR-16-0122. Epub 2016 Jul 25.

47.

Primary Care Requirements for Pharmacists-Clinical Reasoning Education at Schools of Pharmaceutical Sciences.

Ashizawa T.

Yakugaku Zasshi. 2016;136(7):939-44. doi: 10.1248/yakushi.15-00257-2. Review. Japanese.

48.

Sensory and motor cortex function contributes to symptom severity in spinocerebellar ataxia type 6.

Kang N, Christou EA, Burciu RG, Chung JW, DeSimone JC, Ofori E, Ashizawa T, Subramony SH, Vaillancourt DE.

Brain Struct Funct. 2017 Mar;222(2):1039-1052. doi: 10.1007/s00429-016-1263-4. Epub 2016 Jun 28.

49.

Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy.

Gao Y, Guo X, Santostefano K, Wang Y, Reid T, Zeng D, Terada N, Ashizawa T, Xia G.

Mol Ther. 2016 Aug;24(8):1378-87. doi: 10.1038/mt.2016.97. Epub 2016 May 12.

50.

(CAG)n loci as genetic modifiers of age-at-onset in patients with Machado-Joseph disease from mainland China.

Chen Z, Zheng C, Long Z, Cao L, Li X, Shang H, Yin X, Zhang B, Liu J, Ding D, Peng Y, Wang C, Peng H, Ye W, Qiu R, Pan Q, Xia K, Chen S, Sequeiros J, Ashizawa T, Klockgether T, Tang B, Jiang H; Chinese Clinical Research Cooperative Group for Spinocerebellar Ataxias (CCRCG-SCA).

Brain. 2016 Aug;139(Pt 8):e41. doi: 10.1093/brain/aww087. Epub 2016 Apr 16. No abstract available.

PMID:
27085188

Supplemental Content

Loading ...
Support Center